EAACI Prague, 1-3 July 2022

CCC presents results of two-year treatment of birch pollen allergy with mannan-conjugated allergoids.

CCC presents first results of a two-year allergen-specific immunotherapy with depigmented allergoids in patients suffering from allergic rhinitis with or without asthma.

CCC presents the first data from a 5-year cohort study with an MCT-adjunct allergoid. Treatment
outcomes of children and adolescents are compared with those of adults.